---
title: "BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292759741.md"
description: "BioCryst Pharmaceuticals (BCRX) appointed David W. Jenkins as its new Chief Scientific Officer, effective immediately. In this newly created role, Jenkins will lead a research team focused on leveraging external innovation and partnerships to accelerate rare disease therapies. He brings over 20 years of biopharmaceutical experience, most recently serving as Senior Vice President at Ipsen."
datetime: "2026-07-15T11:35:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292759741.md)
  - [en](https://longbridge.com/en/news/292759741.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292759741.md)
generator: "portal-rs"
---

# BioCryst Pharmaceuticals Appoints David Jenkins As Chief Scientific Officer

Add  as your preferred news source on Google

 Add Now

BioCryst Pharmaceuticals, Inc. (BCRX) said on Wednesday that it has appointed David W. Jenkins to the newly created role of Chief Scientific Officer with immediate effect.

In this role, Jenkins will build and lead a research team focused on leveraging external innovation, capabilities, and partnerships to boost the delivery of rare disease therapies to the patients. 

Jenkins worked for over 20 years in the biopharmaceutical industry. He most recently served as Senior Vice President, Head of Research & External Innovation at Ipsen (IPN.PA,I7G.F, IPSEF.P,IPSEY). 

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [BCRX.US](https://longbridge.com/en/quote/BCRX.US.md)

## Related News & Research

- [BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Wednesday](https://longbridge.com/en/news/294186102.md)
- [Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy](https://longbridge.com/en/news/296478943.md)
- [The Bull Case For Vertex (VRTX) Could Change Following Upgraded 2026 Guidance And Pipeline Momentum - Learn Why](https://longbridge.com/en/news/296583461.md)
- [Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves](https://longbridge.com/en/news/296514765.md)
- [Diversify Advisory Services LLC Buys New Holdings in Regeneron Pharmaceuticals, Inc. $REGN](https://longbridge.com/en/news/296585791.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**